denkapparat Operations GmbH Buys 9,222 Shares of Exelixis, Inc. $EXEL

denkapparat Operations GmbH lifted its position in Exelixis, Inc. (NASDAQ:EXEL) by 38.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 33,152 shares of the biotechnology company’s stock after buying an additional 9,222 shares during the period. Exelixis makes up about 0.6% of denkapparat Operations GmbH’s portfolio, making the stock its 25th largest position. denkapparat Operations GmbH’s holdings in Exelixis were worth $1,804,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of EXEL. Motiv8 Investments LLC purchased a new position in shares of Exelixis in the fourth quarter worth $26,000. Cassaday & Co Wealth Management LLC acquired a new position in shares of Exelixis in the 1st quarter valued at $27,000. Acumen Wealth Advisors LLC purchased a new position in Exelixis in the 4th quarter worth $29,000. Western Wealth Management LLC purchased a new position in Exelixis in the 1st quarter worth $29,000. Finally, Northwestern Mutual Wealth Management Co. lifted its position in Exelixis by 1,380.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 773 shares during the period. Institutional investors own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $56.00 target price on shares of Exelixis in a research note on Thursday, July 2nd. Morgan Stanley boosted their price target on Exelixis from $50.00 to $53.00 and gave the company an “equal weight” rating in a report on Thursday, July 23rd. Wall Street Zen lowered Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. UBS Group set a $55.00 price objective on shares of Exelixis in a research note on Monday, August 3rd. Finally, Royal Bank Of Canada boosted their target price on shares of Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $50.07.

Insider Buying and Selling at Exelixis

In other news, Director Mary Beckerle sold 9,812 shares of Exelixis stock in a transaction on Monday, August 10th. The stock was sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the sale, the director directly owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. The trade was a 37.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.60% of the company’s stock.

Exelixis Trading Up 1.0%

NASDAQ:EXEL opened at $59.13 on Friday. The company has a market cap of $14.65 billion, a P/E ratio of 18.59, a P/E/G ratio of 1.74 and a beta of 0.42. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $59.72. The company’s 50-day moving average price is $54.98 and its 200-day moving average price is $49.44.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.85 by $0.06. The firm had revenue of $628.69 million during the quarter, compared to analysts’ expectations of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The business’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.75 earnings per share. On average, analysts expect that Exelixis, Inc. will post 3.19 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.